Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer [0.03%]
Neal D Shore,Nasreen Khan,Rana R McKay et al.
Neal D Shore et al.
Aims: We assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups. ...
Observational Study
Future oncology (London, England). 2026 May;22(11):1311-1319. DOI:10.1080/14796694.2026.2661772 2026
Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy [0.03%]
Rana R McKay,Nasreen Khan,Neal D Shore et al.
Rana R McKay et al.
Aim: Describe real-world anticancer treatment patterns in the USA among patients with prostate cancer (PC) who experience biochemical recurrence (BCR) following radical prostatectomy (RP) or radiation therapy (RT), strati...
Observational Study
Future oncology (London, England). 2026 May;22(11):1301-1309. DOI:10.1080/14796694.2026.2651959 2026
Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma [0.03%]
Enrique M Ocio,Aurore Perrot,Philippe Moreau et al.
Enrique M Ocio et al.
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer [0.03%]
Ludovica Cella,Alessio Finocchiaro,Aleksander Ślusarczyk et al.
Ludovica Cella et al.
Intravesical mitomycin C (MMC) is a cornerstone therapy for non-muscle-invasive bladder cancer (NMIBC), effectively reducing recurrence in low-grade intermediate-risk patients. We conducted a narrative synthesis of randomized and prospectiv...
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery [0.03%]
LAURA研究结果的通俗解读：奥希替尼用于不可手术切除EGFR突变非小细胞肺癌患者化疗联合放疗后的治疗
Shun Lu,Terufumi Kato,Xiaorong Dong et al.
Shun Lu et al.
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies [0.03%]
艾拉纳单抗初治多发性骨髓瘤患者的真实世界治疗模式和结局：来自ALTITUDE 1期研究和ALTITUDE 2回顾性队列研究报告
Rahul Banerjee,Meera Mohan,Bhavesh Shah et al.
Rahul Banerjee et al.
Background and aim: Elranatamab is a bispecific antibody currently approved in the United States (US) for the treatment of relapsed/refractory multiple myeloma (MM). Given its recent approval, real-world data are limited....
Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer [0.03%]
评价zorertinib治疗HER2突变非小细胞肺癌患者的效果
Jinyong Kim,Myung-Ju Ahn
Jinyong Kim
HER2 mutations define a distinct molecular subset of non-small cell lung cancer (NSCLC) associated with poor outcomes and limited benefit from conventional systemic therapies. Zongertinib is a next-generation, HER2-selective irreversible ty...
Protocol for a pilot-randomized trial in newly diagnosed glioblastoma: standard care with or without daily intranasal perillyl alcohol [0.03%]
新诊断的胶质母细胞瘤标准护理联合或不联合每日穿鼻(per)illy醇治疗的试点随机试验方案
Daniela Carneiro de Lima,Axel H Schönthal,Clóvis Orlando Pereira da Fonseca et al.
Daniela Carneiro de Lima et al.
Glioblastoma (GB) is a highly malignant brain tumor with poor prognosis and limited treatment options. Standard treatment, surgery followed by chemoradiation with temozolomide (TMZ), yields an average survival of 18 months. Preclinical stud...
Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis [0.03%]
抗CLDN18.2疗法治疗CLDN18.2阳性晚期或转移性胃、胃食管交界和食管癌疗效和安全性的系统评价和meta分析
Yaping Zhang,Shangbin Kao,Dian Li et al.
Yaping Zhang et al.
Purpose: The optimal treatment strategy for advanced or metastatic gastric, gastro-esophageal junction or esophageal carcinomas expressing Claudin-18 isoform 2 (CLDN18.2) remains inadequately defined and requires further ...
Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design) [0.03%]
布格替尼用于ALK融合阳性实体瘤II期篮式试验：WJOG15221M/ALLBREAK（分散式临床试验设计）
Tomoki Sakakida,Toshiki Masuishi,Takuma Onoe et al.
Tomoki Sakakida et al.
Anaplastic lymphoma kinase (ALK) rearrangements, oncogenic drivers found in 3-5% of non-small cell lung cancer (NSCLC), are also detected in 0.2% of other solid tumors with poor prognosis. Brigatinib, a second-generation ALK-tyrosine kinase...